Final answer:
Trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 receptor and helps to control signaling through HER2. It is used in combination with chemotherapy for the treatment of metastatic breast cancer. Potential toxicities of trastuzumab include fatigue, nausea, diarrhea, and cardiac toxicity.
Step-by-step explanation:
Trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 receptor, which is present in excessive amounts in 20% of human breast cancers. It works by binding to the HER2 receptor and stimulating the immune system to remove the cancer cells. Trastuzumab therapy helps to control signaling through HER2 and is often used in combination with chemotherapy for the treatment of metastatic breast cancer.
Like any medication, trastuzumab can have potential toxicities. The most common side effects include fatigue, nausea, diarrhea, and cardiac toxicity. Cardiac toxicity can manifest as a decrease in heart function or, in rare cases, congestive heart failure. Regular cardiac monitoring is necessary during trastuzumab treatment to detect any potential cardiac issues.